Related Experiment Video
Updated: Mar 16, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.6K
Concerns with beta2-agonists in pediatric asthma - a clinical perspective
Elin T G Kersten1, Gerard H Koppelman1, Bernard J Thio2
1University of Groningen, University Medical Center Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, GRIAC research institute, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Paediatric Respiratory Reviews
|August 13, 2016
Summary
Concerns exist regarding the safety of beta2-adrenoreceptor agonists (β2-agonists) for childhood asthma. Regular use, especially in children aged 4-11, may increase risks of severe exacerbations and asthma-related deaths.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Beta2-adrenoreceptor agonists (β2-agonists) are common asthma treatments for children.
- Concerns about their safety and adverse effects have been raised.
- A 2005 FDA "Black Box Warning" highlighted risks associated with long-acting beta-agonists (LABAs).
Purpose of the Study:
- To review β2-receptor pharmacology.
- To discuss safety concerns of β2-agonists in childhood asthma.
- To provide clinical practice suggestions for pediatricians.
Main Methods:
- Review of current literature.
- Analysis of meta-analysis data on controlled clinical trials.
- Examination of proposed mechanisms for adverse effects.
Main Results:
- Severe adverse events were most frequent in the 4-11 year age group in a meta-analysis.
- Potential risks include masking worsening asthma, receptor desensitization, and pro-inflammatory effects.
- Age-related differences in asthma pathophysiology may contribute to risks.
Conclusions:
- Regular use of β2-agonists in childhood asthma warrants careful consideration due to potential risks.
- Understanding β2-receptor pharmacology and age-specific factors is crucial.
- Evidence-based clinical guidelines are needed to optimize pediatric asthma management.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:30Adrenergic Agonists: Therapeutic Uses
2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
01:26Asthma-II: Pathophysiology and Classification
4.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.4K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.4K